RecruitingNot ApplicableNCT06479616
A Long-term Follow-up Study in Participants Who Received CS-101
A Long-term Follow-up Study Evaluating the Safety and Efficacy of Subjects With β-thalassemia Treated With Base-edited Autologous Hematopoietic Stem Cell (CS-101) Transplantation
Sponsor
Children's Hospital of Fudan University
Enrollment
5 participants
Start Date
Jun 18, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
This is a study to evaluate the long-term safety and efficacy of CS-101 in participants who received CS-101 in study CS -101-03 (NCT06065189)
Eligibility
Min Age: 3 YearsMax Age: 17 Years
Inclusion Criteria2
- Participants (or his or her legally appointed and authorized representative or guardian) must sign and date informed consent form (ICF) and, where applicable, an assent form
- Participants must have received CS-101 infusion in last IIT study
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
GENETICCS-101
Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06479616
Related Trials
ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
NCT063647741 location
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
NCT054775636 locations
Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
NCT066479791 location
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia
NCT0414372426 locations
An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia
NCT063081592 locations